Benitec Biopharma BNTC 深 沪
等待开盘 10-19 09:30:00 美东时间
8.11
-0.350
-4.14%
华盛通- 最 高8.47
- 今 开8.47
- 成交量 15.86万股
- 最 低 8.06
- 昨 收 8.46
- 总市值 2.83亿
- 52周最高 16.76
- 市盈率 静 --
- 换手率 0.45%
- 52周最低 8.06
- 委 比 -19.88%
- 总股本 3488.27万
- 历史最高 5609.5744
- 量 比 1.07
- 振 幅 4.85%
- 历史最低 2.227
- 每 手 1
- 风险率 1.51%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Benitec Biopharma Inc收跌4.14%，成交额129.63万美元
10月20-22日上海黄浦江畔，2026可持续全球领导者大会再度来袭。诺奖、图灵奖得主现场讲述科技未来与趋势，更有“解救”焦虑、内卷时代的网红教授——麦克法兰与...
10-17 06:31
Benitec Biopharma shares are trading higher after the company announced that BB-301 pivotal trial remains on track to begin in mid-2027 and the final pivotal study design is expected to be confirmed in Q1 2027.
Benitec Biopharma shares are trading higher after the company announced that BB-301 pivotal trial remains on track to begin in mid-2027 and the final pivotal study design is expected to be confirmed in Q1 2027.
10-06 01:24
Benitec advances BB-301 gene therapy after FDA feedback
Benitec Biopharma ( ($BNTC) ) has shared an update. On October 5, 2026, Benitec...
10-05 20:28
Benitec Biopharma Announces Regulatory Update Following Type C Meeting with FDA for BB-301 Pivotal Study
Benitec Biopharma announced that the pivotal trial for BB-301 remains on track to begin in mid-2027. The FDA requested additional data, including results from the OPMD Natural History Study, and the final study design is expected to be confirmed in 1Q 2027. Benitec will present interim clinical results from the ongoing Phase 1b/2a study at the ESGCT Annual Congress in October 2026, showcasing 12-month follow-up data for Cohort 1 and interim data ...
10-05 12:00
美股大行评级 | 巴克莱大幅升Strategy目标价至160美元！康宁遭看淡至180美元，较现价仍溢价25%
今日重点评级关注：HC Wainwright & Co.：上调Cardiff Oncology评级至"买入"，目标价9美元；古根海姆：维持Inventiva"买入"评级，目标价从11美元升至14美元
09-16 16:10
Wedbush Maintains Outperform on Benitec Biopharma, Raises Price Target to $17
Wedbush analyst Yun Zhong maintains Benitec Biopharma (NASDAQ:BNTC) with a Outperform and raises the price target from $16 to $17.
09-15 21:38
Benitec Biopharma Q4 EPS $(0.26), Inline
Benitec Biopharma (NASDAQ:BNTC) reported quarterly losses of $(0.26) per share which met the analyst consensus estimate. This is a 38.1 percent increase over losses of $(0.42) per share from the same period last year.
09-15 04:09
Benitec Biopharma Releases Full Year 2026 Financial Results and Provides Operational Update
Benitec Biopharma announced financial results for FY 2026 and provided updates on BB-301 clinical development. Cohort 1 (low dose) completed 12-month follow-up, and Cohort 2 (high dose) was fully enrolled with safe treatments. A Type C FDA meeting discussed pivotal study design, with minutes expected in October. Interim results from the Phase 1b/2a trial will be presented at the ESGCT Congress in October. The company has $180 million in cash. BB-...
09-14 20:00
美股大行评级 | 潜在涨幅129.15%！HC Wainwright & Co.升Q32 Bio(QTTB)目标价至36美元，维持"买入"评级
今日重点评级关注：HC Wainwright & Co.：维持Q32 Bio"买入"评级，目标价从13美元升至36美元；Chardan Capital：维持ProMIS Neurosciences"买入"评级，目标价从20美元升至33美元
07-29 11:37
Wedbush Initiates Coverage On Benitec Biopharma with Outperform Rating, Announces Price Target of $16
Wedbush analyst Yun Zhong initiates coverage on Benitec Biopharma (NASDAQ:BNTC) with a Outperform rating and announces Price Target of $16.
07-28 20:49
